Relmada Therapeutics, Inc. (RLMD) income statement
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$2.85−0.15 (-5.15%)
Close on Nov 18, 2026Market cap $304.54MP/E –Yield –
Relmada Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -94.0%
Financial strength
- Current ratio
- 29.52
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 152.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.47
- Dividend yield
- –
See a number that looks wrong?